What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate
Executive Summary
Acting FDA commissioner Janet Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.
You may also be interested in...
Robert Califf Nominated To Retake FDA Commissioner Role
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face if confirmed to a second stint as the nation's top medtech regulator.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.